More on SPTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.9 Score)

Upcoming Events

- Earnings (12/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:SPTX)
Delayed: 17.60 +0.92 (5.52%)
Prev. Close $16.68  
Open$16.82 
52 Wk High$ 
52 Wk Low$ 
Day High$17.89 
Day Low$16.61 
P/E N/A  
EPS$ 
Volume164,912 

Friends, Peers and Foes (?): PRTC (more...)

Oct 14, 2026 05:14 AM Canaccord Starts Seaport Therapeutics (SPTX) at Buy
Oct 9, 2026 01:00 PM Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Oct 9, 2026 01:00 PM PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Oct 9, 2026 07:00 AM Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Oct 9, 2026 07:00 AM Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Oct 8, 2026 07:04 AM H.C. Wainwright Reiterates Buy Rating on Seaport Therapeutics (SPTX)
Oct 7, 2026 01:00 PM Seaport Therapeutics doses first patient in anxiety disorder trial
Oct 7, 2026 01:00 PM PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Oct 7, 2026 07:00 AM Seaport Therapeutics doses first patient in GlyphAgo anxiety trial
Oct 7, 2026 07:00 AM Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
View All Articles

Entities mentioned with SPTX

View All Entities